^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CDK2 expression

    i
    Other names: CDK2, Cyclin-dependent kinase 2
    Entrez ID:
    1017
    Related biomarkers:
    Expression
    CNA
    Associations

    News

    Trials
    1d
    The in vivo effects of knockdown of long non-coding RNA XIST on fibroid growth and gene expression. (PubMed, FASEB J)
    This analysis also revealed decreased collagen and E2F1 staining nuclei in the XIST knockdown xenografts. These results indicate that downregulation of XIST in fibroids has beneficial therapeutic effects, by reducing tumor growth and the expression of genes involved in cell proliferation, inflammation, and extracellular matrix regulation.
    Preclinical • Journal
    |
    CASP3 (Caspase 3) • MIR200C (MicroRNA 200c) • TGFB1 (Transforming Growth Factor Beta 1) • COL3A1 (Collagen Type III Alpha 1 Chain) • TDO2 (Tryptophan 2,3-Dioxygenase) • E2F1 (E2F transcription factor 1) • XIST (X Inactive Specific Transcript)
    |
    miR-200-c expression • CDK2 expression
    17d
    Mitochondrion-targeted selenium nanoparticles stabilized by Sargassum fusiforme polysaccharides increase reactive oxygen species-mediated antitumour activity. (PubMed, Int J Biol Macromol)
    In animal experiments, SFPS-Tw-SeNPs treatment significantly inhibited the growth of A549 tumour xenografts but did not significantly negatively affect the body of the animals. Overall, SFPS-Tw-SeNPs have the potential to be developed as a pharmaceutical drug to prevent and treat non-small cell lung cancer.
    Journal • PARP Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    CDK2 expression
    30d
    Spatially restricted ecto-5'-nucleotidase expression promotes the growth of uterine leiomyomas by modulating Akt activity. (PubMed, FASEB J)
    Enforced expression of the A2B adenosine receptor (ADORA2B) and ADORA2B-selective agonists similarly suppressed proliferation and inhibited Akt phosphorylation. Collectively, these observations broadly implicate CD73 and reduced extracellular concentrations of adenosine as key regulators of leiomyoma growth and potentially identify novel strategies for clinically managing these common tumors.
    Journal
    |
    CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto) • ADORA2B (Adenosine A2b Receptor)
    |
    CD73 expression • CDK2 expression
    1m
    Piperine, a black pepper compound, induces autophagy and cellular senescence mediated by NF-κB and IL-6 in acute leukemia. (PubMed, BMC Complement Med Ther)
    In addition, piperine increased senescence-associated beta-galactosidase fluorescence intensity by increasing p21 and IL-6 expression while decreasing CDK2 expression in NB4 and MOLT-4 cells. In conclusion, our study provides additional information about the induction of autophagy and senescence by piperine in acute leukemia.
    Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • IL6 (Interleukin 6) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • BECN1 (Beclin 1)
    |
    IL6 expression • CDK2 expression
    1m
    Inhibition of HDAC8 mitigates AKI by reducing DNA damage and promoting homologous recombination repair. (PubMed, J Cell Mol Med)
    In a murine model of AKI induced by cisplatin, the administration of PCI-34051, a selective inhibitor of HDAC8, resulted in significant improvement in renal function and reduction in renal tubular damage and apoptosis. Similarly, pharmacological and genetic inhibition of HDAC8 reduced γ-H2AX and enhanced MRE11 expression; conversely, HDAC8 overexpression exacerbated these changes in mRTECs exposed to cisplatin. These results support that HDAC8 inhibition attenuates cisplatin-induced AKI through a mechanism associated with reducing DNA damage and promoting its repair.
    Journal • PARP Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • HRD (Homologous Recombination Deficiency) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MRE11A (MRE11 homolog, double strand break repair nuclease) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    BCL2 expression • TP53 expression • BAX expression • CDK2 expression
    |
    cisplatin
    1m
    Exploring the therapeutic potential of rabdoternin E in lung cancer treatment: Targeting the ROS/p38 MAPK/JNK signaling pathway. (PubMed, Mol Med Rep)
    Histopathological observation confirmed that the number of tumor cells decreased markedly after administration of rabdoternin E. Taken together, rabdoternin E induced apoptosis and ferroptosis of A549 cells by activating the ROS/p38 MAPK/JNK signaling pathway. Therefore, the results of the present study showed that rabdoternin E is not toxic to MCF‑7 cells (normal lung cells), had no significant effect on body weight and was effective and therefore may be a novel therapeutic treatment for lung cancer.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • GPX4 (Glutathione Peroxidase 4) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    CDK2 expression
    2ms
    Anticancer Activity and Mechanism of Action of Couroupita guianensis Bark Decoction in Gastric Adenocarcinoma Cancer Cell Line. (PubMed, Int J Mol Sci)
    Increased expression or activation of the key proteins (p53, p21, cdk2, Bak, caspases, pAMPK, pAkt, beclin, p62 and LC3BII) involved in these processes was observed. The results obtained confirmed an important anticancer effect of C. guianensis bark decoction, providing scientific validation for its use in traditional medicine and highlighting its potential as a therapeutic agent against gastric cancer.
    Preclinical • Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    CDK2 expression
    2ms
    circRACGAP1 Promotes Proliferation of Non-Small Cell Lung Cancer Cells through the miR-1296/CDK2 Pathway. (PubMed, Folia Biol (Praha))
    Additionally, the dual-luciferase reporter assay and Pearson correlation coefficient analysis proved that circRACGAP1 acted in NSCLC cells by negatively regulating miR-1296 expression and positively regulating CDK2 expression. In summary, our study revealed that circRACGAP1 promoted NSCLC cell proliferation by regulating the miR-1296/CDK2 pathway, providing potential diagnostic and therapeutic targets for NSCLC.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • RACGAP1 (Rac GTPase activating protein 1)
    |
    BCL2 expression • BAX expression • CDK2 expression
    2ms
    Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. (PubMed, Br J Cancer)
    No abstract available
    Preclinical • Review • Journal
    |
    CDK2 (Cyclin-dependent kinase 2)
    |
    CDK2 expression
    5ms
    Pantoprazole suppresses carcinogenesis and growth of hepatocellular carcinoma by inhibiting glycolysis and Na+/H+ exchange. (PubMed, Drug Dev Res)
    Further results showed that PPZ reduced the production of these inflammatory cytokines and the expression of these cell proliferation-associated genes through the inhibition of glycolysis and Na+/H+ exchange. In conclusion, PPZ suppresses the carcinogenesis and growth of HCC, which is related to inhibiting the production of inflammatory cytokines and the expression of cell proliferation-associated genes in the liver through the inhibition of glycolysis and Na+/H+ exchange.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • BIRC5 (Baculoviral IAP repeat containing 5) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • AURKA (Aurora kinase A) • CCL20 (C-C Motif Chemokine Ligand 20) • CCL2 (Chemokine (C-C motif) ligand 2) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CCNB2 (Cyclin B2) • CCNE2 (Cyclin E2) • CDC25C (Cell Division Cycle 25C) • CDK1 (Cyclin-dependent kinase 1) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
    |
    CDK2 expression
    6ms
    The anti-non-small cell lung cancer effect of Diosbulbin B: Targeting YY1 induced cell cycle arrest and apoptosis. (PubMed, Phytomedicine)
    For the inaugural investigation, this research unveiled the anti-NSCLC impact of DIOB, alongside its fundamental mechanism. DIOB has demonstrated potential as a treatment agent for NSCLC due to its impressive efficacy in countering NSCLC.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDK4 (Cyclin-dependent kinase 4) • BAX (BCL2-associated X protein) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • YY1 (YY1 Transcription Factor)
    |
    MYC expression • BAX expression • CDK2 expression
    6ms
    On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation. (PubMed, Sci Rep)
    The antiproliferative effects of wogonin on THP-1 cells of AML-M5 presented a dose-dependent and time-dependent manner, inducing apoptosis, blocking the cell cycle at the G2/M phase, decreasing the expressions of CCND1, CDK2, and CyclinA2 mRNA, as well as AKT and p-AKT proteins. The mechanisms of wogonin on AML-M5 treatment may be associated with inhibiting cell proliferation and regulating the cell cycle via the PI3K/AKT signaling pathway.
    Journal
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • RELA (RELA Proto-Oncogene)
    |
    CCND1 expression • CDK2 expression
    6ms
    Effects of silencing NLRP3 gene on proliferation of psoriasis-like HaCaT cells and expressions of cytokines. (PubMed, Cell Mol Biol (Noisy-le-grand))
    Compared with negative control group, expressions of NLRP3 mRNA and protein, proliferation rate and clonal formation rate were decreased in NLRP3-RNAi group, percentage of cells in G0/G1 phase was increased, percentage of cells in S phase was decreased, expressions of Cyclin B1, CDK2, Ki67 and PCNA proteins were decreased, and levels of IL-17, IL-23, IL-6 and TNF-α were decreased. Silencing NLRP3 gene can inhibit the proliferation of psoriasis-like HaCaT cells, arrest cell cycle, inhibit the expressions of cell proliferation-related proteins and reduce levels of pro-inflammatory factors.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDK2 (Cyclin-dependent kinase 2) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • PCNA (Proliferating cell nuclear antigen) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CCNB1 (Cyclin B1)
    |
    CDK2 expression • PCNA expression
    6ms
    Apoptotic Effect of Isoimpertorin via Inhibition of c-Myc and SIRT1 Signaling Axis. (PubMed, Int J Mol Sci)
    Furthermore, Isoimperatorin suppressed the overexpression of c-Myc by the proteasome inhibitor MG132 and also disturbed cycloheximide-treated c-Myc stability in Huh7 cells. Overall, these findings support the novel evidence that the pivotal role of c-Myc and SIRT1 is critically involved in Isoimperatorin-induced apoptosis in HCCs as potent molecular targets in liver cancer therapy.
    Journal • PARP Biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SIRT1 (Sirtuin 1)
    |
    MYC overexpression • MYC expression • CCND1 expression • CCNE1 expression • CDK2 expression • CDK6 expression
    |
    MG132
    7ms
    circDDX17 targets miR-223-3p / RIP3 to regulate the proliferation and apoptosis of non-small cell lung cancer cells (PubMed, Zhonghua Zhong Liu Za Zhi)
    Percentage of G0/G1 phase cells &lsqb;(56.64±2.76)%], apoptosis rate &lsqb;(8.34±0.76)%], the protein expression levels of cleaved caspase-3 and Bax in pcDNA-circDDX17+miR-223-3p group were lower than those of pcDNA-circDDX17+miR-con group &lsqb;(64.03±3.48)% and (15.21±1.18)%, respectively, P<0.05]. circDDX17 could inhibit the proliferation and induce apoptosis of non-small cell lung cancer cells via targeting the miR-223-3p / RIP3 molecular axis.
    Journal
    |
    CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • MIR223 (MicroRNA 223) • DDX17 (DEAD-Box Helicase 17)
    |
    CCND1 expression • BAX expression • CDK2 expression
    7ms
    "Keep on ROCKIn": Repurposed ROCK inhibitors to boost corneal endothelial regeneration. (PubMed, Biomed Pharmacother)
    In compared parameters, Chroman-1 at a concentration of 10 nM outperformed other ROCKi, requiring significantly 1000-fold lower effective concentration than established ROCKi Y-27632 and Fasudil. Altogether, this study underscores the potential of repurposing ROCKi for treating corneal endothelial dysfunctions, offering a viable alternative to conventional grafting methods, and highlights Chroman-1 as a promising candidate structure for hit-to-lead development.
    Journal
    |
    CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2) • TJP1 (Tight Junction Protein 1)
    |
    CCNE1 expression • CDK2 expression
    8ms
    The p53-mediated cell cycle regulation is a potential mechanism for emodin-suppressing osteosarcoma cells. (PubMed, Heliyon)
    Emodin at 10 μM decreased the expression of Cdk2, E2F, and Cdk1; and increased RB but had no effects on cyclin E and cyclin B. The knockdown of p53 almost eliminated all the impacts of 10 μM emodin on cell cycle proteins. Emodin suppresses U2OS by p53-mediated cell cycle regulation.
    Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    TP53 mutation • TP53 expression • CDK2 expression
    8ms
    Activation of Bivalent Gene POU4F1 Promotes and Maintains Basal-like Breast Cancer. (PubMed, Adv Sci (Weinh))
    Knocking out POU4F1 in BLBC cells reactivates functional ERα expression, rendering BLBC sensitive to tamoxifen treatment. In-depth epigenetic analysis reveals that the subtype-specific re-configuration and activation of the bivalent chromatin in the POU4F1 promoter contributes to its unique expression in BLBC, which is maintained by DNA demethylase TET1. Together, these results reveal a subtype-specific epigenetically activated TF with critical role in promoting and maintaining BLBC, suggesting that POU4F1 is a potential therapeutic target for BLBC.
    Journal
    |
    ER (Estrogen receptor) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • CCND1 (Cyclin D1) • CDK2 (Cyclin-dependent kinase 2)
    |
    CDK2 expression
    |
    tamoxifen
    8ms
    Rujifang inhibits triple-negative breast cancer growth via the PI3K/AKT pathway. (PubMed, J Ethnopharmacol)
    RJF demonstrates effectiveness and safety in the context of TNBC. It exerts anti-tumor effects by arresting the cell cycle at the S phase through the PI3K-AKT pathway.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    CDK2 expression
    |
    cyclophosphamide
    8ms
    Combination therapy application of Abemaciclib with Doxorubicin in triple negative breast cancer cell line MDA-MB-231. (PubMed, Cell Mol Biol (Noisy-le-grand))
    For this reason, in this study, we aimed to determine the impact of the combined use of the CDK4/6 inhibitors ABE and DOX on the cytotoxicity, apoptotic homeostasis, alterations in antioxidative mechanisms, and the molecular pathways that they utilize. Our results showed that when used in combination, Doxorubicin and Abemaciclib showed a synergistic effect on TNBC cell line MDA-MB-231.
    Preclinical • Journal • Combination therapy • PARP Biomarker
    |
    CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2)
    |
    CDK2 expression
    |
    doxorubicin hydrochloride • Verzenio (abemaciclib)
    8ms
    Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in Pancreatic Cancer. (PubMed, Anticancer Res)
    Flavopiridol potentiates the anti-tumor activity of gemcitabine by inducing cell cycle arrest and apoptosis. Its synergistic inhibition of PDAC cell proliferation, when combined with gemcitabine, positions flavopiridol as a promising candidate for cancer treatment.
    Journal • Combination therapy
    |
    CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2)
    |
    CDK2 expression
    |
    gemcitabine • alvocidib (DSP-2033)
    8ms
    MicroRNA-485-5p targets keratin17 to regulate pancreatic cancer cell proliferation and invasion via the FAK / SRC / ERK pathway. (PubMed, J Cancer)
    The silenced KRT17 remarkably downregulated the expression of cyclinD1, Cyclin Dependent Kinase 1 (CDK1), CDK2, Phospho-Focal Adhesion Kinase (p-FAK), p-Src, and p-ERK proteins in the PC cells. Generally, an essential signaling cascade of miRNA-485-5p/KRT17/FAK/Src/ERK influences the biological functions of PC cells.
    Journal
    |
    CCND1 (Cyclin D1) • KRT7 (Keratin-7) • CDK2 (Cyclin-dependent kinase 2) • KRT17 (Keratin 17) • CDK1 (Cyclin-dependent kinase 1) • MIR485 (MicroRNA 485)
    |
    CCND1 expression • KRT17 overexpression • KRT7 expression • CDK2 expression
    8ms
    Prohibitin 1 inhibits cell proliferation and induces apoptosis via the p53-mediated mitochondrial pathway in vitro. (PubMed, World J Gastrointest Oncol)
    PHB1 inhibits human HCC cell viability by arresting the cell cycle and inducing cell apoptosis via activation of the p53-mediated mitochondrial pathway.
    Preclinical • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CCNE1 (Cyclin E1) • AFP (Alpha-fetoprotein) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    TP53 expression • BAX expression • CDK2 expression
    8ms
    3-Amide-β-carbolines block the cell cycle by targeting CDK2 and DNA in tumor cells potentially as anti-mitotic agents. (PubMed, Bioorg Chem)
    Moreover, M3 and D4 interact with DNA and CDK2 at sub-micromolar concentrations in endothermic interactions caused by entropy-driven adsorption processes, which means that the favorable entropy change (ΔS > 0) overcomes the unfavorable enthalpy change (ΔH > 0) and drives the spontaneous reaction (ΔG < 0). Overall, these results clarified the antitumor mechanisms of M3 and D4 through disrupting the cell cycle by binding DNA and CDK2, which demonstrated the potential of M3 and D4 as novel antiproliferative drugs targeting mitosis.
    Journal • Tumor cell
    |
    CDK2 (Cyclin-dependent kinase 2)
    |
    CDK2 expression
    8ms
    Targeting glutamine metabolism exhibits anti-tumor effects in thyroid cancer. (PubMed, J Endocrinol Invest)
    Thyroid cancer exhibited enhanced glutamine metabolism, as evidenced by the glutamine dependence of thyroid cancer cells and high expression of multiple glutamine metabolism-related genes. Targeting glutamine metabolism with DON prodrug could be a promising therapeutic option for advanced thyroid cancer.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • MMP2 (Matrix metallopeptidase 2) • VIM (Vimentin) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • GLS1 (Glutaminase)
    |
    VIM expression • CDK2 expression
    |
    JHU083
    9ms
    FOXM1 promote the growth and metastasis of uveal melanoma cells by regulating CDK2 expression. (PubMed, Int Ophthalmol)
    FOXM1 silencing may hinder UVM cell progression, providing a novel theoretical basis and new insights for UVM treatment.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CDK2 (Cyclin-dependent kinase 2) • FOXM1 (Forkhead Box M1) • CCNB1 (Cyclin B1)
    |
    CDK2 expression
    9ms
    Synthesis, docking, MD simulation, ADMET, drug likeness, and DFT studies of novel furo[2,3-b]indol-3a-ol as promising Cyclin-dependent kinase 2 inhibitors. (PubMed, Sci Rep)
    The methods utilized included molecular docking, density functional theory (DFT) calculations using the B3LYP/6-31++G(d,p) basis set in the gas phase, molecular dynamic (MD) simulation, as well as the evaluation of drug-likeness scores. The pharmacokinetic and drug-likeness properties of the novel furo&lsqb;2,3-b]indol-3a-ol derivatives suggest that these compounds have the potential to be considered viable candidates for future development as anticancer drugs.
    Journal
    |
    CDK2 (Cyclin-dependent kinase 2)
    |
    CDK2 expression
    9ms
    Jaceosidin induces apoptosis and inhibits migration in AGS gastric cancer cells by regulating ROS-mediated signaling pathways. (PubMed, Redox Rep)
    Furthermore, N-acetyl cysteine pre-treatment prevented the change of these protein expressions. In summary, JAC induced apoptosis and G0/G1 phase arrest and inhibited migration through ROS-mediated signaling pathways in AGS cells.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CDK6 (Cyclin-dependent kinase 6) • CDK2 (Cyclin-dependent kinase 2) • CDH2 (Cadherin 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    CCND1 expression • CDH1 expression • CDK2 expression • CDK6 expression
    9ms
    Risk model based on genes regulating the response of tumor cells to T-cell-mediated killing in esophageal squamous cell carcinoma. (PubMed, Aging (Albany NY))
    Drug sensitivity analysis demonstrated lower IC50 for AZD6244 and PD.0332991 in high-risk groups and lower IC50 for cisplatin, ATRA, QS11, and vinorelbine in the low-risk group. Furthermore, the differential expression of GRTTK-related signatures including CDK2, TCEA1, and TMEM209 were verified in ESCC tissues and paracancerous tissues. Overall, the novel GRTTK-based prognostic model can serve as indicators to predict the survival status and immunotherapy response of patients with ESCC, thereby providing guidance for the development of personalized treatment strategies.
    Journal • IO biomarker • Tumor cell
    |
    CDK2 (Cyclin-dependent kinase 2) • EIF4H (Eukaryotic Translation Initiation Factor 4H)
    |
    CDK2 expression
    |
    cisplatin • Ibrance (palbociclib) • Koselugo (selumetinib) • vinorelbine tartrate
    10ms
    Immune infiltration related CENPI associates with the malignant features and drug resistance of lung adenocarcinoma. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    What's more, the knock down of CENPI inhibited the expression of CDK2 in lung adenocarcinoma (LUAD), and resulted in the arrest of G0/G1 phase and apoptosis. Besides, CENPI was related to immune cells infiltration and drug sensitivity in pan-cancer, and can act as a potential treatment target to cure cancer patients.
    Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • CENPI (Centromere Protein I)
    |
    CDK2 expression
    10ms
    Exploring the Molecular Targets and Therapeutic Potential of Coptisine in Colon Cancer: A Network Pharmacology Approach. (PubMed, Curr Med Chem)
    Coptisine may be a candidate drug for the treatment of colon cancer, and its therapeutic effect may be related to the cancer pathway and PI3K-Akt signalling pathway. CCNE1 and HSP90AB1 may be potential targets of coptisine in the treatment of colon cancer.
    Journal • PARP Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • CCNE1 (Cyclin E1) • CHEK2 (Checkpoint kinase 2) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CDK2 (Cyclin-dependent kinase 2) • CDC42 (Cell Division Cycle 42) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)
    |
    CDK2 expression
    10ms
    KLF14 activates the JNK-signaling pathway to induce S-phase arrest in cervical cancer cells. (PubMed, Front Immunol)
    KLF14 also activated the JNK pathway to induce S-phase arrest and promote the expression of CDK2 and CCNA2. In summary, KLF14 activates the JNK-signaling pathway to induce S-phase arrest in cervical cancer cells.
    Journal
    |
    CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • KLF14 (KLF Transcription Factor 14) • MAPK8 (Mitogen-activated protein kinase 8)
    |
    KLF4 overexpression • CCNA2 expression • CDK2 expression
    10ms
    Boswellia carterii oleoresin extracts induce caspase-mediated apoptosis and G cell cycle arrest in human leukaemia subtypes. (PubMed, Front Pharmacol)
    Cytotoxic mechanisms likely include activation of the intrinsic apoptotic pathway and cell cycle arrest through downregulation of CDK2, CDK6, cyclin D1, and cyclin D3. Our findings suggest that B. carterii may be an important source of novel chemotherapeutic drugs and justifies further investigation.
    Journal
    |
    CCND1 (Cyclin D1) • CDK6 (Cyclin-dependent kinase 6) • CASP3 (Caspase 3) • CCND3 (Cyclin D3) • CDK2 (Cyclin-dependent kinase 2) • ANXA5 (Annexin A5)
    |
    CCND1 expression • CDK2 expression • CDK6 expression
    10ms
    miR-181b-5p promotes cell proliferation and induces apoptosis in human acute myeloid leukemia by targeting PAX9 (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
    Compared with miR-181b-5p group, proliferation activity of cells, percentage of cells in S phase, and expressions of CDK2, CCNB1 and Bcl2 proteins were decreased, while percentage of cells in G0/G1 phase, apoptosis rate and the expression of BAX protein were increased in miR-181b-5p combined with PAX9 group. Conclusion The miR-181b-5p can promote the proliferation of AML cells and delay apoptosis by inhibiting PAX9.
    Journal • IO biomarker
    |
    BAX (BCL2-associated X protein) • CDK2 (Cyclin-dependent kinase 2) • CCNB1 (Cyclin B1) • MIR181B1 (MicroRNA 181b-1)
    |
    BCL2 expression • BAX expression • CDK2 expression
    11ms
    Long non-coding RNA generated from CDKN1A gene by alternative polyadenylation regulates p21 expression during DNA damage response. (PubMed, Nucleic Acids Res)
    Like CDKN1A full-length isoform, SPUD can bind two competitive p21 translational regulators, the inhibitor calreticulin and the activator CUGBP1; SPUD alters their association with CDKN1A full-length in a DDR-dependent manner, promoting CDKN1A translation. Together, these results show a new regulatory mechanism by which a lncRNA controls p21 expression post-transcriptionally, highlighting lncRNA relevance in DDR progression and cell-cycle.
    Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • CALR (Calreticulin) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    CDK2 expression
    11ms
    Aridanin and oleanane-3- O-β-D-glucoside-2'-acetamide obtained from Tetrapleura tetraptera (Schumach. & Thonn) Taub. (Fabaceae) induces potent apoptotic activity in human prostate cancer cells. (PubMed, J Ethnopharmacol)
    This study outlines for the first time, the anticancer ability of compounds oleanane-3-O-β-D-glucoside-2'-acetamide (4) and aridanin (6) from Tetrapleura tetraptera and proposes their putative mechanisms of action.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • VIM (Vimentin) • CDK2 (Cyclin-dependent kinase 2)
    |
    CDK2 expression
    12ms
    Small-molecule exhibits anti-tumor activity by targeting the RNA mA reader IGF2BP3 in ovarian cancer. (PubMed, Am J Cancer Res)
    The pharmacodynamic models of two kinds of OC bearing animals were suggested that systemic therapy with AE-848 significantly inhibited tumor growth by reducing the expression of tumor-associated antigen (c-MYC/VEGF/Ki67/CDK2) and improving the anti-tumor effect of macrophages. These results suggest that AE-848 can inhibit the growth and progression of OC cells by disrupting the stability of the targeted mRNAs of IGF2BP3 and may be a targeted drug for OC treatment.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CDK6 (Cyclin-dependent kinase 6) • CDK2 (Cyclin-dependent kinase 2) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
    |
    MYC expression • CDK2 expression
    1year
    Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer. (PubMed, Oncol Rep)
    Therefore, the present study demonstrated that LCA effectively inhibited cell proliferation and induced apoptosis in vitro, and suppressed xenograft tumor growth in vivo. LCA may serve as a future therapeutic candidate of LSCC.
    Journal • PARP Biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • FBXO5 (F-Box Protein 5)
    |
    CCND1 expression • BAX expression • PARP1 expression • CDK2 expression
    1year
    Red Kale (Brassica oleracea L. ssp. acephala L. var. sabellica) Induces Apoptosis in Human Colorectal Cancer Cells In Vitro. (PubMed, Molecules)
    Furthermore, the study identified certain bioactive compounds, such as sinigrin, spirostanol, hesperetin and usambarensine, which could potentially contribute to the apoptotic effect of red kale extracts. However, further investigations are necessary to elucidate the specific role of these individual compounds in the anti-cancer process.
    Preclinical • Journal
    |
    CDK4 (Cyclin-dependent kinase 4) • MAPK1 (Mitogen-activated protein kinase 1) • CDK2 (Cyclin-dependent kinase 2) • CASP9 (Caspase 9) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK10 (Mitogen-Activated Protein Kinase 10)
    |
    TP53 expression • CDK2 expression
    1year
    Effects of Echinacoside on Ehrlich Carcinoma in Rats by Targeting Proliferation, Hypoxia and Inflammation. (PubMed, Cureus)
    Conclusions Our research found that echinacoside has antitumor properties that resulted in a substantial decrease in tumor size and weight, leading to an increase in the average survival time of rats and an improvement in muscle structure. Additionally, echinacoside was shown to ameliorate hypoxia by suppressing HIF-1α, reduce inflammation by decreasing NFκB and TNF-α, decrease proliferation by reducing PI3K, and block cyclin D1 and CDK2 to inhibit differentiation.
    Preclinical • Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • CCND1 (Cyclin D1) • TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    CCND1 expression • HIF1A expression • CDK2 expression
    1year
    CDK2-activated TRIM32 phosphorylation and nuclear translocation promotes radioresistance in triple-negative breast cancer. (PubMed, J Adv Res)
    Our findings demonstrate that regulating the CDK2/TRIM32/STAT3 pathway is a promising strategy for reducing radioresistance in TNBC.
    Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • TRIM3 (Tripartite Motif Containing 3)
    |
    CDK2 expression